Summary-Percutaneous left atrial appendage (LAA) occlusion is an alternative therapeutic option for stroke prevention in patients with atrial fibrillation and contraindications for oral anticoagulation. There are few data available regarding the technical success of percutaneous LAA closure in patients with the previous implantation of an atrial septal defect (ASD) or a patent foramen ovale closure device. This is the description of a case of a successful LAA closure performed with an Amplatzer Amulet occluder device (St. Jude Medical, Inc., St. Paul, MN, USA) in a patient with a previous history of percutaneous ASD.
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C erebral embolism, the most common complication of non-valvular atrial fibrillation (NVAF), typically occurs due to a thrombus formation in the left atrium (LA), predominantly in the left atrial appendage (LAA). Systemic anticoagulation is the standard of care for the prevention of cerebral and peripheral thromboembolism among NVAF patients with a high risk score. However, some patients with a high risk score are not suitable for anticoagulant therapy, particularly when there is the risk of bleeding. LAA occlusion is an effective therapeutic option (either percutaneous or surgical) for such patients. [1, 2] The transseptal puncture performed during a percutaneous closure of LAA is one of the most important and rate-limiting steps of the procedure. Previously, it has been proposed that percutaneous LAA closure was contraindicated in patients with a history of atrial septal defect (ASD), patent foramen ovale (PFO) closure device, or surgical interatrial septal defect closure. [3] There are few case reports in the literature regarding percutaneous LAA closure in patients with a previous ASD or PFO closure device. [4, 5] Therefore, herein, the case of a successful percutaneous LAA closure performed in a patient with a history of an ASD closure device is described.
CASE REPORT
A 79-year-old woman was referred to the clinic for a percutaneous LAA closure due to a history of recurrent lower gastrointestinal bleeding and blood transfusions under 2 different oral anticoagulants. She
Received: December 10,  and TEE guidance without any leakage or instability after appropriate maneuvers (Tug test) (Figs. 2a-e) .
DISCUSSION
Thromboembolism is known to be one of the most important clinical events in patients with NVAF. Vitamin K antagonists and new oral anticoagulant drugs are very effective at reducing the thromboembolism risk; however, these agents can create minor and/or major bleeding risks for those patients. [6] [7] [8] [9] LAA closure is an emerging interventional therapeutic option, especially in patients with a high risk for bleeding or embolic events under oral anticoagulation. [10, 11] However, the presence of an occluder device in the interatrial septum is a major limitation for LAA occlusion using percutaneous methods and transseptal access. Despite this difficulty, previous reports have revealed favorable outcomes after interatrial septal closure, especially in the presence of appropriate interatrial septal tissue. Gafoor et al. [5] reported successful LAA occlusion in patients with prior septal closure devices. Similarly, in a recent case report, Heersink et al. [4] reported successful LAA occlusion after percutaneous ASD closure using a Watchman device (Boston Scientific, Corp., Marlborough, MA, USA). Furthermore, Gloekler et al. [12] also performed a transseptal puncture, perforated and pre-dilated the lower disc of the ASD closure device, and successfully finished the LAA closure procedure as well as deployment of an additional small ASD closure device at the site of puncture. Our case appears to be the first with the successful deployment of the Amulet device in a patient with a history of previous percutaneous ASD closure. The location of the transseptal puncture during percutaneous LAA closure is the critical step that provides a technical advantage. In addition to the LAA morphology, device characteristics may also affect procedural success due to the limited interatrial septal area available for transseptal puncture, as it may limit maneuverability of the operator during the procedure. We recommend both fluoroscopic and TEE-guidance during the procedure, not only for optimal device deployment, but also to achieve an optimal transseptal puncture.
